NEW YORK , Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby , Chief Scientific Officer, will participate in a panel discussion at the

- Third Quarter includes Delivery of Approximately 134,000 Courses of TPOXX® to U.S. Government – - In October, the Public Health Agency of Canada Announced its Intent to Purchase up to 33,300 Courses of Oral TPOXX® – - Corporate Update Conference Call Today at 4:30 PM ET   - NEW YORK , Nov.

NEW YORK , Oct. 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M.

P ublic Health Agency of Canada Contract would be Second Contract by a Canadian Governmental Agency   for the Procurement of Oral TPOXX Delivery of 18,500 Courses   by March 31, 2023 ; Delivery of Additional 14,800 Courses   Subject to Option Exercise NEW YORK , Oct.

NEW YORK , Sept. 10, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez , SIGA’s Chief Executive Officer, will participate in a fireside chat at the Cantor

NEW YORK , Aug. 31, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby , SIGA’s Chief Scientific Officer, has been named a recipient of the 2021 American

- Second Quarter includes Deliveries to SNS and First International Delivery - - Corporate Update Conference Call Today at 4:30 PM ET   - NEW YORK , Aug. 06, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health